Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

A 3D illustration depicting Cancer Cells in the crosshairs, related to cancer treatment
Pharma firms are pursuing new ways of addressing known targets • Source: Shutterstock

More from Emerging Company Profiles

More from Anticancer